$907 Million is the total value of Cormorant Asset Management, LP's 84 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 23.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALDR | ALDER BIOPHARMACEUTICALS INC | $55,351,000 | +31.2% | 1,689,071 | 0.0% | 6.10% | +2.1% | |
| NVRO | NEVRO CORP | $51,260,000 | +41.5% | 491,044 | 0.0% | 5.65% | +10.1% | |
| TBPH | THERAVANCE BIOPHARMA INC | $40,530,000 | +59.7% | 1,118,372 | 0.0% | 4.47% | +24.2% | |
| NERV | MINERVA NEUROSCIENCES INC | $39,522,000 | +38.2% | 2,800,000 | 0.0% | 4.36% | +7.5% | |
| PTI | Buy | PROTEOSTASIS THERAPEUTICS IN | $36,636,000 | +123.0% | 2,350,000 | +73.5% | 4.04% | +73.4% |
| CLSD | CLEARSIDE BIOMEDICAL INC | $34,496,000 | +147.5% | 1,988,208 | 0.0% | 3.80% | +92.5% | |
| EGRX | Sell | EAGLE PHARMACEUTICALS INC | $31,920,000 | +62.6% | 455,995 | -9.9% | 3.52% | +26.5% |
| HRTX | HERON THERAPEUTICS INC | $30,519,000 | -4.5% | 1,771,263 | 0.0% | 3.36% | -25.8% | |
| ARDX | Buy | ARDELYX INC | $26,811,000 | +104.9% | 2,071,964 | +38.2% | 2.96% | +59.3% |
| MYOK | Buy | MYOKARDIA INC | $26,239,000 | +179.0% | 1,605,790 | +111.8% | 2.89% | +117.0% |
| CLVS | New | CLOVIS ONCOLOGY INC | $23,433,000 | – | 650,000 | +100.0% | 2.58% | – |
| ACRS | ACLARIS THERAPEUTICS INC | $23,082,000 | +38.7% | 901,286 | 0.0% | 2.54% | +7.8% | |
| QTNT | Buy | QUOTIENT LTD | $21,800,000 | +82.9% | 2,787,717 | +81.3% | 2.40% | +42.2% |
| GLPG | GALAPAGOS NVspon adr | $21,441,000 | +16.9% | 334,044 | 0.0% | 2.36% | -9.1% | |
| MGNX | MACROGENICS INC | $21,176,000 | +10.8% | 707,978 | 0.0% | 2.34% | -13.8% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $20,170,000 | +11.4% | 398,301 | 0.0% | 2.22% | -13.4% | |
| OMER | Sell | OMEROS CORP | $18,916,000 | +5.2% | 1,695,000 | -0.9% | 2.09% | -18.2% |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $16,904,000 | – | 800,000 | +100.0% | 1.86% | – |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $16,492,000 | +102.1% | 507,907 | +28.8% | 1.82% | +57.2% |
| SRNE | SORRENTO THERAPEUTICS INC | $16,417,000 | +38.2% | 2,121,013 | 0.0% | 1.81% | +7.5% | |
| CHRS | COHERUS BIOSCIENCES INC | $15,428,000 | +58.6% | 576,106 | 0.0% | 1.70% | +23.3% | |
| CBPO | CHINA BIOLOGIC PRODS INC | $14,050,000 | +17.1% | 112,867 | 0.0% | 1.55% | -9.0% | |
| CRBP | CORBUS PHARMACEUTICALS HLDGS | $13,580,000 | +127.1% | 2,000,000 | 0.0% | 1.50% | +76.7% | |
| PTLA | Buy | PORTOLA PHARMACEUTICALS INC | $13,535,000 | +44.8% | 596,000 | +50.5% | 1.49% | +12.7% |
| CLLS | CELLECTIS S Asponsored ads | $11,995,000 | -9.4% | 498,117 | 0.0% | 1.32% | -29.6% | |
| AGEN | AGENUS INC | $11,331,000 | +77.3% | 1,578,106 | 0.0% | 1.25% | +38.0% | |
| IVTY | Buy | INVUITY INC | $10,530,000 | +3130.1% | 767,466 | +2144.1% | 1.16% | +2423.9% |
| ADXS | Buy | ADVAXIS INC | $9,845,000 | +50.3% | 920,915 | +13.7% | 1.09% | +16.9% |
| GEMP | New | GEMPHIRE THERAPEUTICS INC | $9,828,000 | – | 900,000 | +100.0% | 1.08% | – |
| CFRX | Buy | CONTRAFECT CORP | $9,526,000 | +292.0% | 3,840,966 | +356.7% | 1.05% | +204.3% |
| INCR | INC RESH HLDGS INCcl a | $8,916,000 | +16.9% | 200,000 | 0.0% | 0.98% | -9.1% | |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $8,876,000 | +333.0% | 298,870 | +195.3% | 0.98% | +236.4% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $8,773,000 | +62.5% | 455,515 | 0.0% | 0.97% | +26.4% | |
| DXCM | DEXCOM INC | $8,766,000 | +10.5% | 100,000 | 0.0% | 0.97% | -14.0% | |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $8,548,000 | -23.1% | 126,120 | -37.1% | 0.94% | -40.2% |
| ACHN | ACHILLION PHARMACEUTICALS | $8,150,000 | +3.8% | 1,006,128 | 0.0% | 0.90% | -19.2% | |
| BOLD | New | AUDENTES THERAPEUTICS INC | $8,008,000 | – | 449,660 | +100.0% | 0.88% | – |
| EBS | New | EMERGENT BIOSOLUTIONS INC | $7,883,000 | – | 250,000 | +100.0% | 0.87% | – |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $7,863,000 | +45.0% | 110,842 | 0.0% | 0.87% | +12.7% | |
| ARRY | New | ARRAY BIOPHARMA INC | $7,763,000 | – | 1,150,000 | +100.0% | 0.86% | – |
| FLGT | New | FULGENT GENETICS INC | $7,376,000 | – | 800,000 | +100.0% | 0.81% | – |
| FWP | FORWARD PHARMA A/Ssponsored adr | $7,123,000 | +15.6% | 339,175 | 0.0% | 0.78% | -10.2% | |
| SGMO | SANGAMO BIOSCIENCES INC | $6,493,000 | -20.0% | 1,402,331 | 0.0% | 0.72% | -37.8% | |
| CRIS | Buy | CURIS INC | $6,292,000 | +242.7% | 2,410,900 | +104.9% | 0.69% | +166.9% |
| ZYNE | ZYNERBA PHARMACEUTICALS INC | $6,271,000 | +90.5% | 480,501 | 0.0% | 0.69% | +48.2% | |
| REPH | Sell | RECRO PHARMA INC | $5,916,000 | -4.4% | 669,239 | -14.0% | 0.65% | -25.7% |
| CTMX | CYTOMX THERAPEUTICS INC | $5,827,000 | +53.5% | 371,636 | 0.0% | 0.64% | +19.5% | |
| DERM | DERMIRA INC | $5,820,000 | +15.6% | 172,083 | 0.0% | 0.64% | -10.1% | |
| PFNX | PFENEX INC | $5,661,000 | +6.9% | 632,559 | 0.0% | 0.62% | -16.9% | |
| AVXS | New | AVEXIS INC | $5,434,000 | – | 131,858 | +100.0% | 0.60% | – |
| CATB | New | CATABASIS PHARMACEUTICALS IN | $4,928,000 | – | 800,000 | +100.0% | 0.54% | – |
| INTEC PHARMA LTD JERUSALEM | $4,762,000 | +27.9% | 809,804 | 0.0% | 0.52% | -0.6% | ||
| XLRN | ACCELERON PHARMA INC | $4,612,000 | +6.5% | 127,451 | 0.0% | 0.51% | -17.1% | |
| ONS | ONCOBIOLOGICS INC | $4,366,000 | +25.0% | 1,027,216 | 0.0% | 0.48% | -2.8% | |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $4,241,000 | – | 1,155,600 | +100.0% | 0.47% | – |
| LBIO | LION BIOTECHNOLOGIES INC | $4,164,000 | +1.6% | 505,941 | 0.0% | 0.46% | -21.0% | |
| ATRA | ATARA BIOTHERAPEUTICS INC | $3,988,000 | -5.0% | 186,460 | 0.0% | 0.44% | -26.1% | |
| AGRX | AGILE THERAPEUTICS INC | $3,936,000 | -8.3% | 563,880 | 0.0% | 0.43% | -28.6% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $3,645,000 | +72.6% | 240,403 | +12.1% | 0.40% | +34.4% |
| CRVS | CORVUS PHARMACEUTICALS INC | $3,522,000 | +15.3% | 214,132 | 0.0% | 0.39% | -10.4% | |
| LPCN | LIPOCINE INC NEW | $3,351,000 | +46.7% | 751,296 | 0.0% | 0.37% | +14.2% | |
| IMDZ | IMMUNE DESIGN CORP | $3,282,000 | -7.1% | 432,990 | 0.0% | 0.36% | -27.7% | |
| APTOSE BIOSCIENCES INC | $2,229,000 | -7.8% | 990,579 | 0.0% | 0.25% | -28.3% | ||
| RGNX | REGENXBIO INC | $2,196,000 | +75.1% | 156,741 | 0.0% | 0.24% | +36.0% | |
| GLYC | GLYCOMIMETICS INC | $2,052,000 | -1.7% | 287,031 | 0.0% | 0.23% | -23.6% | |
| AQXP | AQUINOX PHARMACEUTICALS INC | $2,029,000 | +101.9% | 151,838 | 0.0% | 0.22% | +56.6% | |
| CYAD | CELYAD SAadr | $1,791,000 | -5.5% | 75,920 | 0.0% | 0.20% | -26.8% | |
| EPZM | EPIZYME INC | $1,570,000 | -3.9% | 159,513 | 0.0% | 0.17% | -25.4% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $1,251,000 | +51.5% | 62,254 | 0.0% | 0.14% | +17.9% | |
| FOLD | AMICUS THERAPEUTICS INC | $1,124,000 | +35.6% | 151,838 | 0.0% | 0.12% | +5.1% | |
| AVEO | AVEO PHARMACEUTICALS INC | $968,000 | -7.4% | 1,087,715 | 0.0% | 0.11% | -27.7% | |
| NSTG | NANOSTRING TECHNOLOGIES INC | $809,000 | +58.6% | 40,490 | 0.0% | 0.09% | +23.6% | |
| THLD | THRESHOLD PHARMACEUTICAL INC | $686,000 | +6.7% | 1,012,255 | 0.0% | 0.08% | -16.5% | |
| ONSIZ | ONCOBIOLOGICS INC*w exp 05/18/201 | $500,000 | +167.4% | 416,666 | 0.0% | 0.06% | +103.7% | |
| HTGM | HTG MOLECULAR DIAGNOSTICS IN | $472,000 | -10.8% | 203,464 | 0.0% | 0.05% | -30.7% | |
| GNVC | Sell | GENVEC INC | $468,000 | -31.4% | 1,015,685 | -14.7% | 0.05% | -46.4% |
| NEOS | NEOS THERAPEUTICS INC | $333,000 | -29.1% | 50,613 | 0.0% | 0.04% | -44.8% | |
| PVCT | PROVECTUS BIOPHARMACEUTICALS | $221,000 | -73.2% | 2,226,961 | 0.0% | 0.02% | -79.5% | |
| ONSIW | ONCOBIOLOGICS INC*w exp 02/18/201 | $199,000 | +3.6% | 416,666 | 0.0% | 0.02% | -18.5% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $178,000 | -13.6% | 25,307 | 0.0% | 0.02% | -31.0% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $169,000 | -31.0% | 17,321 | 0.0% | 0.02% | -45.7% | |
| CLRB | CELLECTAR BIOSCIENCES INC | $145,000 | -21.6% | 53,649 | 0.0% | 0.02% | -38.5% | |
| PVCTW | PROVECTUS BIOPHARMACEUTICALS*w exp 06/19/202 | $114,000 | -72.5% | 2,200,000 | 0.0% | 0.01% | -78.0% | |
| CLRBW | CELLECTAR BIOSCIENCES INC*w exp 08/20/201 | $13,000 | -55.2% | 52,999 | 0.0% | 0.00% | -75.0% | |
| Exit | TETRALOGIC PHARMACEUTICALS Cnote 8.000% 6/1 | $0 | – | -5,000,000 | -100.0% | -0.12% | – | |
| AGIO | Exit | AGIOS PHARMACEUTICALS INC | $0 | – | -50,000 | -100.0% | -0.30% | – |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -253,064 | -100.0% | -1.04% | – |
| RLYP | Exit | RELYPSA INC | $0 | – | -450,000 | -100.0% | -1.18% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -635,000 | -100.0% | -1.31% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -1,619,608 | -100.0% | -1.67% | – |
| VTAE | Exit | VITAE PHARMACEUTICALS INC | $0 | – | -1,754,795 | -100.0% | -2.68% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -730,000 | -100.0% | -3.12% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -2,022,879 | -100.0% | -4.08% | – |
| TSRO | Exit | TESARO INC | $0 | – | -362,875 | -100.0% | -4.32% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.